


Proteomics goes Clinical, or does it?



Salerno, July 2012

Meilahti Clinical Proteomics Core Facility

Biomedicum Helsinki and Haartman Institute, 00014
University of Helsinki, Finland

E-Mail: marc.baumann@helsinki.fi

(<http://research.med.helsinki.fi/corefacilities/proteinchem>)

Services

- Proteomic services from Bedside-to-Bench
- High-throughput analysis of Clinical Samples (CSF, Saliva, Urine, Blood, Ascites, Tears etc.)
- Validation of Clinical Samples
- Validation of Clinical Biomarkers

- Basic Proteomics Analyses (1-2D-GE, 1-2D-LC)
- Ion Mobility Structural Analyses

- Array-based epitope mapping (Pep/Prot-Arrays)
- Pep-Array synthesis
- Imaging Mass Spectrometry (IMS) from tissue to cells
- Glycoproteomics
- Glycopeptidomics
- LC-MS/MS2 analysis of carbohydrates
- N-glycopeptide spectra analysis
- Core fucosylation analysis

Services



ProtMet.net






Over 1200 Researchers in only Medical Research
(Cancer, Genetics, Developmental Medicine, Neuroscience etc.)

The Medical Faculty





Proteomics

What is it all about??

Proteomic Research

The main objectives today for clinical and general Proteomics:

- **Quantification** of all the proteins expressed in a cell or tissue proteome, body fluids e.g. blood, CSF etc. Searching for Biomarkers!
- **Functional study** of thousands of proteins in parallel, which protein is in contact to another protein and where? Searching for functionality!

For quantification purposes, standard **method** is 2DE electrophoresis or MudPIT separation followed by MS identification

For protein function studies, microarray based assays are used to study protein-protein and protein-ligand interactions

SEEING GRAVITY WAVES

21ST-CENTURY SLAVERY

SCIENTIFIC AMERICAN

APRIL 2012 \$4.95
WWW.SAONLINE.COM

Proteomics


Biotech's
Next Big
Challenge

PLUS:
Virtual Captions
for the Real World
Fighting Dad Death

© 2012 SCIENTIFIC AMERICAN

SCIENTIFIC AMERICAN™

Permanent Address: <http://www.scientificamerican.com/article.cfm?id=proteins-rule>



Proteins Rule

Biotech's latest mantra is "proteomics," as it focuses on how dynamic networks of human proteins control cells and tissues

By Carol Ezzell | Wednesday, April 24, 2002 | 0


Move over, human genome, your day in the spotlight is coming to a close. Researchers are now concentrating

Scientific American is a trademark of Scientific American, Inc., used with permission

© 2011 Scientific American, a Division of Nature America, Inc.

All Rights Reserved.






The Post-Genome Project

Whether The Human Proteome Will Be Successfully Mapped In Three Years Depends On How You Define "Proteome"

By [Karen Hopkin](#) | August 17, 2001 | [0](#)



Vol. 14 No. 3

www.ddmag.com

Advantage
Business Media

DRUG

DISCOVERY & DEVELOPMENT

STRATEGIES & TECHNOLOGIES DRIVING DRUG DISCOVERY TO MARKET

A Long Way to the Bedside

Despite many
breakthroughs
Proteomics has not
translated yet to
patient care



■ March 2011

■ Policy and Projections
ESCAPE STRATEGY

■ Assay Development
METABOLOMICS

■ Drug Safety
FMT IMAGING

■ Informatics
DATA VISUALIZATION

■ How It Works
CLINICAL TRIAL DATA



MPI Research...
Your responsive
CRO partner.

See next page
for more information.

Recent years have seen rapid technological progress in the fields supporting personalized medicine, from biomarker discovery to mapping the genome to pushing back the frontiers of mass spec sensitivity. However, thus far, little of that progress has translated to the clinic where it can benefit patients.

**personalized
medicine has not
translated yet to
patient care.**

CLINICAL TRIAL DATA



**MPI Research...
Your responsive
CRO partner.**

See next page
for more information.

Success rate of biomarker search
which would be in clinical use:

0

2010

How can we make Proteomics
more suitable to the "real" life?


The technology...

2D gel electrophoresis

2D liquid chromatography

Micro arrays

We need a technology to find changes in Proteome




A protein Array

Administration of a drug known to bind to an orphan receptor

- **Changes in expression level of 23 proteins**

Two-dimensional gel electrophoresis (2D) could do it?


- 1st dimension, IEF, Proteins are separated according to their isoelectric point (IP)
- 2nd dimension, SDS-PAGE, Proteins are separated according to their molecular mass
- Efficient: More than a thousand proteins resolved in E-Coli cell lysates and ~8000 in brain lysates



2nd Dimension - Isoelectric Focusing

2DE

M_w




Protein Fingerprint: 2-DE

200

Mr
(kDa)

15



4.1





pI

6.9

About 2000
proteins



Overlay of normal and patient protein samples




Normal control = CyTM3 labelled - Blue

Patient A sample = Cy5 Labelled - Red





EttanTM DiGE
the quantitative approach to do Proteomics

Low-Abundance Protein Enrichment Hexapeptide Kits Useful for Many Sample Types








Proteominer BioRad

Micro gel devices








Running time 10 minutes




Automated 2D devices

The compress system






And the big brother (2011)



Regular size automated 2DE

2-D map of IEF standards



Repeatability of 2-DE runs

Rf values (%) [*]		pI position errors(%) [*]	
STDV	6,1	STDV	2,5
max	15	max	6
min	0,8	min	0,6

^{*} comparison of 3 gels


- 2-DE separation completed in **approx. 80 min**
- Limit of detection is **approx. 65 ng**

Running time 20-30 minutes

Examples for the Clinics

- Performance

- Native IEF and native PAGE
 - 5 variants of hemoglobin
 - pH 6.7 -7.7



- Native IEF and SDS-PAGE
 - standard IEF proteins
 - pH 3-10



- Denatured IEF and SDS-PAGE
 - GFAP protein variants expression differences
 - in control and Alzheimer diseased patients
 - pH 4-6




control




AD

TARGETED measurements of unknown protein expression differences:


Application: Screening of protein variations of viruses or bacteria



Normal virus




Normal virus +
mutated virus (LT)






Normal virus +
mutated virus (HT)

Also 2D Databases exist!





What about chip-based proteomics: DIOS-MS

Desorption Ionization On Silicon (DIOS)



Testing the functionality of various surfaces for proteomics




Signal intensity of unphosphorylated peptide 2423 (left) and phosphorylated peptide 2422 (right) from different surfaces.

Application: Phosphoproteomics, determination of phosphorylation states (kinasome)



The μ MOTC-nESI Lab-on-a-Chip

In collaboration with Prof. Evangelos Gogolides, Athens

Black Silica chip



384 samples (e.g. phosphopeptides)



10800 samples on the chip

Application: Array based Proteomics



Array-based epitope mapping


1. Peptide synthesis on membrane





2. Peptide/Protein spotting on glass slide





3. Analysis by AB, dyes or MS






Affinity chip with microfluidistics



3.58 K X
Apr 2008 Time :12:09:28



Several affinities to choose from



High Sample Throughput for the
Post-Genomic Era and Clinical use
(35000 samples/week)



MALDI-TOF(TOF)-MS




Twister

Prespotted AnchorChip targets dedicated for Clinical Proteomics



- > no cross contamination
- > no memory effects
- > Easy storing and archiving of targets
- > Re-visiting of samples
- > One calibrant, four matrix spots for samples
- > 10-100 fold increased sensitivity, in situ sample purification





Bruker Daltonics GmbH


MALDI TOF/TOF




Schematic diagram of a Reflector MALDI-TOF mass spectrometer.

MALDI-TOF = Matrix Assisted Laser Desorption/Ionization - Time Of Flight

Quadrupole TOF/TOF








2D-LC
UPLC

MALDI


Quadrupole TOF/TOF



Ion Mobility driftscope view





Ion Mobility driftscope view



Even with the most sophisticated LC-based MS instruments of today we will possibly not be able to use them for high-throughput clinical sample screening?


Although the time for one analysis in theory is fast...

UPLC™ increases Speed by 9X (900%)





Increased sample throughput

In the reality you can analyze a few hundred compounds in a few hours...



You can then combine several analyzes to get thousands of compounds measured



If you want to quantify those, you need to run several serial analyses of each sample (label-free quantification)

Or use isotopic labeling (ITRAQ, ICAT, SILAC)

In any case


One sample needs approx. 24-38 hours of instrument time!

>>> One instrument can handle a few clinical sample series a year

Proteomics chip technology for LC

The whole 2D LC can be done in a chip

- Sub-2-micron chromatographic performance
- Eliminates manual connections
- Low system volumes
- Integrated emitter and electronic components



TRIZAIC™
UPLC SYSTEM




The whole 2D LC can be done in a chip


- Submicron channels
- High performance
- Eliminate column connections
- Low flow rates
- Integrated electronics




NanoSpray LC/MS



High throughput CE



LED detection (MIT, Forest et al, 2006)




Ultra-high throughput CE chips for proteomics



Geniom chips

-Currently for DNA/RNA
analysis


(Development ongoing
for proteome analysis)

Capacity approx. 40000 ligands






A set of thousands of Mass Spectrometers in one chip



Other techniques to help in proteomics?

- Tissue microdissection**
- Imaging MS**

Why Tissue Microdissection?



You would like to isolate only the targeted diseased tissue

Laser-based microdissection:



Capturing of the vessels in the control brain slide

Cap or tube



Slide before capture



Slide after capture



MALDI MS analysis directly from the tissue captured on the cap membrane



Filter Aided Sample Preparation (FASP)



Whole tissue homogenated in SDS

>> centrifuge in a 10 kD co filter

Digest with trypsin

Change SDS to Urea

Filter again

>> run MS (approx 30-40% more proteins)

TECHNICAL BRIEF


Comparison between procedures using SDS for shotgun proteomic analyses of complex samples

Michael S. Bereman, Jarrett D. Egertson and Michael J. MacCoss


Proteomics 2011, 11, 2931–2935 DOI 10.1002/pmic.201100045 2931

Whole Cell and Protein Microarray Chip structures

Electroporation on a chip: Cell trapping






Single cell electroporation



H. Andersson and A. van den Berg, "Microfluidic devices for cellomics: a review," *Sensors and Actuators B*, **92** (3), (2003), 315-325.

Lab on a Chip course, Finland, 2006

Cell trapping and - lysis Chip structures for single Cell Proteomics?




Development of Integrated Nanoliter Analysis Devices (DDTC-Viikki, Microtechnology Center-HUT, Biomedicum Helsinki)

The TIME component!



MALDI mass spectrometric imaging of biological tissue sections for protein imaging

Principles




- A laser is rastered over a defined area while acquiring a complete mass spectrum from each position, resulting in molecular images for multiple analytes

Cornett, et al., Nature Methods 2007



Tissue slide for IMS



MALDI Imaging of Formalin-Fixed Paraffin-Embedded Tissues: Application to Model Animals of Parkinson Disease for Biomarker Hunting

J. Stauber,^{§†} R. Lemaire,^{§†} J. Franck,[†] D. Bonnel,[†] D. Croix,[†] R. Day,[‡] M. Wisztorski,[†]
I. Fournier,^{*†} and M. Salzet^{*†}

Clathrate nanostructures for mass spectrometry


Trent R. Northen^{1,2*}, Oscar Yanes^{1,2*}, Michael T. Northen⁴, Dena Marrinucci³, Winnie Uritboonthai^{1,2},
Junefredo Apon^{1,2}, Stephen L. Golledge⁵, Anders Nordström^{1,2} & Gary Siuzdak^{1,2*}

MALDI imaging mass spectrometry: molecular snapshots of biochemical systems

Dale S Cornett, Michelle L Reyzer, Pierre Chaurand & Richard M Caprioli

Benefits of MALDI-IMS

- Analysis of entire sample in one reading
- Previous knowledge of molecular composition is not necessary
- Allows for investigation of disease formation, progression, and treatment




a




optical
1 mm

b



m/z 8258
100%
0%

c




m/z 6716
100%
0%



d




m/z 2584
100%
0%




IMS vs. histochemical stain



Imaging Lipidomics



Imaging Proteomics



M. Reid Groseclose, Malin Andersson,
Richard M. Caprioli ASMS 2006, poster
presentation

Localization of water-soluble carbohydrates in wheat stems using imaging matrix-assisted laser desorption ionization mass spectrometry

Sarah Robinson¹, Karen Warburton³, Mark Seymour², Malcolm Clench³ and Jane Thomas-Oates¹

¹Department of Chemistry, University of York, Heslington, York YO10 5DD, UK; ²Syngenta, Jealott's Hill International Research Centre, Bracknell, Berkshire RG42 6EY, UK; ³Biomedical Research Centre, Sheffield Hallam University, Howard Street, Sheffield S1 1WB, UK







Fig. 2 Example photographs of (a) a longitudinal section and (b) a cross section through a piece of wheat (*Triticum aestivum*) stem before positioning in the matrix-assisted laser desorption ionization (MALDI) source of the mass spectrometer.









New Phytologist (2007) **173**: 438–444



3D IMS-MS




a spectrum
per pixel





Spatial distribution of AD amyloid beta peptide In brain tissue

= not detectable by AB staining



Diagnostic value?


Imaging Mass Spectrometry (IMS) of a Specific Fragment of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Kinase 2 Discriminates Cancer from Uninvolved Prostate Tissue

Lisa H. Cazares,^{1,2,3} Dean Troyer,^{1,3} Savvas Mendrinos,³ Raymond A. Lance,^{3,5} Julius O. Nyalwidhe,^{1,2,3} Hind A. Beydoun,⁴ Mary Ann Clements,^{1,2,3} Richard R. Drake,^{1,2,3} and O. John Semmes^{1,2,3}


Clin Cancer Res 2009;15(17) September 1, 2009

IMS and protein arrays


1 DIRECT IMMUNOHISTOCHEMISTRY




You can create TAGⁿ







2 LASER DESORPTION



3 SPECIFIC MASS SPECTROMETRY IMAGING





Proteomics goes Clinical, or does it?

Hopefully 😊



same Genome - different *Proteome*

B I O M E D I C U M H E

8

